MCID: PRT037
MIFTS: 65

Pertussis

Categories: Infectious diseases, Rare diseases, Respiratory diseases, Smell/Taste diseases

Aliases & Classifications for Pertussis

MalaCards integrated aliases for Pertussis:

Name: Pertussis 12 74 52 58 3 15 71
Whooping Cough 12 74 52 58 42 3 15 17 32
Bordetella Infections 43 17 71
Whooping Cough Due to Unspecified Organism 71
Bordetella Pertussis Infection 52
Bordetella Infection 12
Wc - Whooping Cough 12

Characteristics:

Orphanet epidemiological data:

58
whooping cough
Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1116
MeSH 43 D001885
MESH via Orphanet 44 D014917
ICD10 via Orphanet 33 A37.0 A37.1 A37.8 more
UMLS via Orphanet 72 C0043167 C0043168
Orphanet 58 ORPHA1489
UMLS 71 C0006015 C0043167 C0043168

Summaries for Pertussis

MedlinePlus : 42 Whooping cough is an infectious bacterial disease that causes uncontrollable coughing. The name comes from the noise you make when you take a breath after you cough. You may have choking spells or may cough so hard that you vomit. Anyone can get whooping cough, but it is more common in infants and children. It's especially dangerous for infants. The coughing spells can be so bad that it is hard for infants to eat, drink, or breathe. To make a diagnosis, your doctor may do a physical exam, blood tests, chest x-rays, or nose or throat cultures. Before there was a vaccine, whooping cough was one of the most common childhood diseases and a major cause of childhood deaths in the U.S. Now most cases are prevented by vaccines. If you have whooping cough, treatment with antibiotics may help if given early. Centers for Disease Control and Prevention

MalaCards based summary : Pertussis, also known as whooping cough, is related to tetanus and haemophilus influenzae, and has symptoms including fever, pruritus and snoring. An important gene associated with Pertussis is TLR4 (Toll Like Receptor 4), and among its related pathways/superpathways are Pertussis and Innate Immune System. The drugs Montelukast and Edetic Acid have been mentioned in the context of this disorder. Affiliated tissues include respiratory tract, neutrophil and smooth muscle, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A commensal bacterial infectious disease that results in inflammation located in respiratory tract, has material basis in Bordetella pertussis, or has material basis in Bordetella parapertussis, which produce toxins that paralyze the cilia of the respiratory epithelial cells. The infection is characterized by a prolonged, high-pitched, deeply indrawn breath (whoop).

CDC : 3 Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Pertussis is known for uncontrollable, violent coughing which often makes it hard to breathe. After cough fits, someone with pertussis often needs to take deep breaths, which result in a "whooping" sound. Pertussis can affect people of all ages, but can be very serious, even deadly, for babies less than a year old. The best way to protect against pertussis is by getting vaccinated

Wikipedia : 74 Whooping cough, also known as pertussis or the 100-day cough, is a highly contagious bacterial disease.... more...

Related Diseases for Pertussis

Diseases related to Pertussis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 834)
# Related Disease Score Top Affiliating Genes
1 tetanus 32.2 TNF IL6 IL1B IL1A IL10
2 haemophilus influenzae 31.9 TNF CXCL8
3 cholera 31.5 TNF IL6 IL1B GNAI1 FOS CXCL8
4 rubella 31.3 TNF TLR4 IL6 IL1B IL10
5 measles 31.3 TNF TLR4 MYD88 IL6 IL1B CXCL8
6 mumps 31.3 TNF IL6 IL1B IL10 CXCL8
7 pulmonary hypertension 31.1 TNF IL6 IL1B IL10 CXCL8
8 encephalitis 31.1 TNF IL6 IL1B IL10
9 pain agnosia 31.1 OPRM1 IL6 IL1B FOS
10 chickenpox 31.0 TNF IL6 IL10
11 neutrophil migration 31.0 MAPK1 ITGB2 ITGAM CXCL8
12 pleurisy 30.9 TNF TLR4 CXCL8
13 hepatitis a 30.9 TNF TLR4 IL1B IL10 CXCL8
14 respiratory failure 30.8 TNF TLR4 JUN IL6 IL1B IL10
15 lymphocytic choriomeningitis 30.8 MYD88 IL6 CXCL8
16 amebiasis 30.8 TNF TLR4 IL1B CXCL8
17 food allergy 30.8 TNF TLR4 IL10 CXCL8
18 bronchiolitis 30.8 TNF TLR4 IL6 IL1A IL10 CXCL8
19 allergic asthma 30.8 TLR4 ITGB2 ITGAM IL10 CXCL8
20 typhoid fever 30.8 TNF TLR4 IL6 IL1B IL1A
21 bronchopneumonia 30.7 TNF TLR4 IL6 IL1B IL10 CXCL8
22 bronchitis 30.7 TNF TLR4 IL6 IL1B IL10 CXCL8
23 sleep disorder 30.7 TNF IL6 IL1B FOS
24 sudden infant death syndrome 30.7 TNF IL6 IL1B IL1A IL10 CXCL8
25 neuroblastoma 30.7 TNF OPRM1 MAPK1 JUN IL6 IL1B
26 erythema multiforme 30.6 TNF IL6 CXCL8
27 bone resorption disease 30.6 TNF IL6 IL1B FOS
28 autoimmune uveitis 30.6 TNF IL1B IL10
29 exanthem 30.6 TNF IL6 IL1B IL10 CXCL8
30 influenza 30.6 TNF TLR4 MYD88 IL6 IL1B IL1A
31 post-transplant lymphoproliferative disease 30.6 TNF IL6 IL1A IL10
32 meningoencephalitis 30.6 TNF IL6 IL1B IL10
33 morphine dependence 30.6 OPRM1 FOS ADCY10
34 hepatitis b 30.6 TNF TLR4 MYD88 IL6 FOS CXCL8
35 thyroiditis 30.6 TNF IL6 IL10
36 neuritis 30.5 TNF IL6 IL1B IL10 CXCL8
37 laryngitis 30.5 TNF IL6 IL1B IL1A
38 myelitis 30.5 TNF IL6 IL10 CXCL8
39 orchitis 30.5 TNF IL6 IL1B IL10
40 pulmonary edema 30.5 TNF IL1B IL10 CXCL8
41 cellulitis 30.5 TNF IL6 IL1B IL10
42 autoimmune disease 30.4 TNF ITGAM IL6 IL1B IL1A IL10
43 chlamydia pneumonia 30.4 TNF TLR4 IL6 IL1B IL10 CXCL8
44 leprosy 3 30.4 TNF TLR4 IL6 IL1B IL10 CXCL8
45 leukostasis 30.4 TNF IL6 IL1B
46 purpura 30.4 TNF IL6 IL10
47 fibrosarcoma 30.4 TNF MAPK1 JUN IL1A FOS
48 stomatitis 30.4 TNF TLR4 IL6 IL1B IL10 CXCL8
49 tularemia 30.4 TNF TLR4 MYD88 IL1B
50 bacterial pneumonia 30.4 TNF TLR4 IL6 IL1B IL10 CXCL8

Graphical network of the top 20 diseases related to Pertussis:



Diseases related to Pertussis

Symptoms & Phenotypes for Pertussis

UMLS symptoms related to Pertussis:


fever, pruritus, snoring, coughing

GenomeRNAi Phenotypes related to Pertussis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 CXCL8 IL10 IL1A IL1B JUN MYD88
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 CXCL8 IL10 IL1B JUN MYD88 TNF
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.47 JUN

MGI Mouse Phenotypes related to Pertussis:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 ADCY10 FOS GNAI1 GNAZ IL10 IL1A
2 hematopoietic system MP:0005397 10.38 FOS GNAI1 GNAZ IL10 IL1A IL1B
3 cellular MP:0005384 10.31 ADCY10 FOS IL10 IL6 ITGAM ITGB2
4 behavior/neurological MP:0005386 10.3 FOS GNAI1 GNAZ IL10 IL6 JUN
5 cardiovascular system MP:0005385 10.29 ADCY10 IL10 IL1A IL1B IL6 ITGB2
6 immune system MP:0005387 10.28 FOS GNAI1 IL10 IL1A IL1B IL6
7 nervous system MP:0003631 10.2 FOS GNAI1 GNAZ IL10 IL1B IL6
8 integument MP:0010771 10.18 FOS GNAZ IL10 IL1A IL1B IL6
9 neoplasm MP:0002006 10.02 FOS IL10 IL1A IL1B IL6 MAPK1
10 no phenotypic analysis MP:0003012 9.86 ADCY10 GNAI1 IL10 JUN MAPK10 MYD88
11 reproductive system MP:0005389 9.85 ADCY10 FOS GNAZ IL10 IL6 MAPK1
12 skeleton MP:0005390 9.7 FOS GNAI1 IL10 IL1B IL6 ITGB2
13 vision/eye MP:0005391 9.28 FOS IL10 IL6 ITGB2 JUN MAPK1

Drugs & Therapeutics for Pertussis

Drugs for Pertussis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Montelukast Approved Phase 4 158966-92-8 5281040
2
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
3
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
4
Pentetic acid Approved Phase 4 67-43-6
5
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
6
BCG vaccine Investigational Phase 4
7 Leukotriene Antagonists Phase 4
8 Vaccines Phase 4
9 Antitoxins Phase 4
10 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
11 Adjuvants, Immunologic Phase 4
12 Aluminum phosphate Phase 4
13 Antidotes Phase 4
14 Chelating Agents Phase 4
15 Iron Chelating Agents Phase 4
16 Calcium, Dietary Phase 4
17 Anticoagulants Phase 4
18 Micronutrients Phase 4
19 Trace Elements Phase 4
20 Chrysanthemum Phase 4
21 Antibodies Phase 4
22 Immunoglobulins Phase 4
23
Calcium Nutraceutical Phase 4 7440-70-2 271
24
Deferiprone Approved Phase 3 30652-11-0 2972
25
Lactitol Approved, Investigational Phase 3 585-88-6, 585-86-4 493591
26
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
27
tannic acid Approved Phase 3 1401-55-4
28
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
29
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
30 Benralizumab Approved, Investigational Phase 2, Phase 3 1044511-01-4
31 Rho(D) Immune Globulin Phase 3
32 gamma-Globulins Phase 3
33 Hemagglutinins Phase 3
34 Laxatives Phase 3
35 Cathartics Phase 3
36 taxane Phase 3
37 Pharmaceutical Solutions Phase 3
38 Respiratory System Agents Phase 2, Phase 3
39 Anti-Asthmatic Agents Phase 2, Phase 3
40
Histidine Investigational, Nutraceutical Phase 2, Phase 3 71-00-1 6274
41
Aluminum sulfate Approved Phase 1, Phase 2 10043-01-3
42
Ibuprofen Approved Phase 2 15687-27-1 3672
43
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
44
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
45
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
46 Prednisolone acetate Approved, Vet_approved Phase 1, Phase 2 52-21-1
47
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
48
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
49
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
50
Basiliximab Approved, Investigational Phase 1, Phase 2 152923-56-3, 179045-86-4

Interventional clinical trials:

(show top 50) (show all 429)
# Name Status NCT ID Phase Drugs
1 Safety and Immunogenicity of Adult Formulation Tetanus and Diphtheria Toxoids Adsorbed Combined With Acellular Pertussis (Tdap) Vaccine Following Blood and Morrow Transplantation in Adults Unknown status NCT00336115 Phase 4
2 Open Label Multicentric Randomized Phase IV Post Marketing Safety, Immunogenicity and Lot-to-Lot Consistency Analysis of Shan 5 [DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine] in Indian Infants Unknown status NCT00877357 Phase 4
3 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
4 Comparison of Two Vaccinal Schemes for DTP-Pertussis-Hib Primo-immunisation in Very Preterm-born Neonates: a Randomised Bicentric Controlled Study Unknown status NCT02179996 Phase 4
5 The Influence of BCG Vaccine as a Booster TDaP-IPV Vaccination: an Explorative Study Unknown status NCT02771782 Phase 4
6 An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age Unknown status NCT00870350 Phase 4
7 Clinical Study to Generate a Set of Data Characterising Clinical Events, Physiological Responses, and Innate and Adaptive Immune Responses Following a Single IM Immunisation With Boostrix® or Placebo in Healthy Adults Unknown status NCT02555540 Phase 4
8 A Double Blind Randomised Placebo Controlled Trial of Montelukast in the Treatment of Acute Persistent Cough in Young People and Adults in Primary Care Unknown status NCT01279668 Phase 4 Montelukast;Placebo
9 Safety Among Adolescents and Adults of Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) 4 to 5 Years After a Previous Dose Completed NCT00347958 Phase 4
10 Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACEL™ and BOOSTRIX® Completed NCT00319553 Phase 4
11 A Randomised Controlled Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants Completed NCT02145624 Phase 4 Repevax;Boostrix-IPV
12 An Open Label Multicentric Study to Evaluate the Immunogenicity and Safety of Indigenously Developed DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine (Shan 5) in Indian Infants. Completed NCT00617812 Phase 4
13 Immune Responses in Adults to Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose Completed NCT00712959 Phase 4
14 Regulatory Post-Marketing Surveillance (PMS) Study for ADACEL™ (Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined Vaccine for Adult) Completed NCT01137435 Phase 4
15 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Young Adults 10 Years After Previous dTpa Boosting. Completed NCT00610168 Phase 4
16 A Single Blind, Multicentric, Comparative, Vaccine Interchangeability Trial of Shan 5 (Liquid) and Easy Five (Liquid) [Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib Pentavalent Combination Vaccines] in Indian Infants. Completed NCT00674908 Phase 4
17 Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) in Persons ≥65 Years of Age Completed NCT00457249 Phase 4
18 A Phase III/IV Randomised Open-label Study and Comparison of the Immunogenicity and Safety of a Single Adolescent Booster Dose of a Meningococcal Group C Conjugate-containing Booster Vaccine (Meningitec™, OR NeisVac-C™ , OR Menitorix™), When Given Concurrently With an Acellular Pertussis-containing Booster Vaccine (Repevax™ or IPV-Boostrix™) Completed NCT02526394 Phase 4 Pertussis containing vaccine
19 Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination Completed NCT00304265 Phase 4
20 Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand Completed NCT02408926 Phase 4
21 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
22 Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting. Completed NCT00635128 Phase 4
23 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
24 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
25 Impact of Pertussis Vaccination in Pregnancy on Maternal Protection Offered to Young Infants Completed NCT01698346 Phase 4
26 Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIM™(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis) Completed NCT01437423 Phase 4
27 Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age. Completed NCT00514059 Phase 4 Boostrix polio
28 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Adults, Given 10 Years After Previous dTpa Boosting. Completed NCT00548171 Phase 4
29 Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexa™ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02853929 Phase 4
30 A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age Completed NCT01357720 Phase 4
31 Safety and Immunogenicity of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
32 A Prospective, Randomized, Open-label Clinical Trial to Assess the Safety and Immunogenicity of Simultaneous vs Sequential Administration of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and Inactivated Influenza Vaccine in Pregnant Women - Pilot Completed NCT02783170 Phase 4
33 Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ (HCP20/20/5/3DT-mIPV//PRP-T) Completed NCT00802867 Phase 4
34 Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine) Completed NCT00777257 Phase 4
35 Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
36 Phase IV, Open Label Trial to Evaluate Immunogenicity of Tdap Vaccine in Post-Partum Women to Optimize Vaccination Schedule for Women Who May Have a Subsequent Child Completed NCT01711645 Phase 4
37 Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
38 Safety & Immunogenicity of a Booster Dose of dTPa Vaccine (Boostrix®) Co-admnd. With Aventis Pasteur's Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Vaccine (Menactra™) vs Admn. of Either Vaccine Alone in Healthy Adolescents Completed NCT00282295 Phase 4
39 Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa™) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
40 Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIM™ in the Study E2I34 Completed NCT01031303 Phase 4
41 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
42 Non-specific Effects of Vaccines - In Search of the Immunological Background Completed NCT00168545 Phase 4
43 A Phase IV Study to Evaluate the Primary and Booster Immune Responses of UK Infants Receiving a Licensed 6-in-1 DTaP/IPV/Hib/HBV Vaccine (Infanrix-HexaTM) With a 13-valent Pneumococcal Conjugate Vaccine and Incorporating a Randomisation Study of a Single Dose of 3 Different Meningococcal Group C Conjugate Vaccines at 3 Months of Age Completed NCT01896596 Phase 4
44 A Phase IV, Randomized Study to Evaluate the Immune Response of UK Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life Completed NCT00625677 Phase 4
45 Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants Completed NCT01926015 Phase 4
46 Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination Completed NCT01323959 Phase 4
47 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine Completed NCT01424644 Phase 4
48 A Phase 4, Randomized, Open-label Trial Evaluating the Safety, Tolerability, and Immunogenicity of DTaP Vaccine in Healthy Infants Given With a 7-valent Pneumococcal Conjugate Vaccine in Japan. Completed NCT01250756 Phase 4
49 An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of VAQTA™ Given Concomitantly With PedvaxHIB™ and Infanrix™ in Healthy Children 15 Months of Age Completed NCT00289913 Phase 4
50 A Phase IV (Not Interventional), Open-label, Multicentre Study to Evaluate the Reactogenicity and Safety of Co-administration of GlaxoSmithKline Biologicals' DTPa (Infanrix) and IPV (Poliorix) Vaccines Administered as Three-dose Primary Immunisation Course at 3, 4.5 and 6 Months of Age in Healthy Children in Russian Federation Completed NCT01094171 Phase 4

Search NIH Clinical Center for Pertussis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ERYTHROMYCIN PWDR
Guaifenesin

Cochrane evidence based reviews: bordetella infections

Genetic Tests for Pertussis

Anatomical Context for Pertussis

The Foundational Model of Anatomy Ontology organs/tissues related to Pertussis:

19
Respiratory Tract

MalaCards organs/tissues related to Pertussis:

40
Neutrophil, Smooth Muscle, Endothelial, Testes, T Cells, Brain, Lung

Publications for Pertussis

Articles related to Pertussis:

(show top 50) (show all 28476)
# Title Authors PMID Year
1
Fever After Influenza, Diphtheria-Tetanus-Acellular Pertussis, and Pneumococcal Vaccinations. 61 42
32029684 2020
2
Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants. 61 42
32027629 2020
3
Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2019. 61 42
31971933 2020
4
Coverage rates of the children vaccination programme in Greenland. 61
32000619 2020
5
Indole alkaloids from leaves of Alstonia scholaris (L.) R. Br. protect against emphysema in mice. 61
32387234 2020
6
Effectiveness of strategies to increase uptake of pertussis vaccination by new parents and family caregivers: A systematic review. 61
32470666 2020
7
Canonical and non-canonical Wnt signaling are simultaneously activated by Wnts in colon cancer cells. 61
32283254 2020
8
D-Peptide analogues of Boc-Phe-Leu-Phe-Leu-Phe-COOH induce neovascularization via endothelial N-formyl peptide receptor 3. 61
32152757 2020
9
SARS - CoV-2: Reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis). 61
32387756 2020
10
Allele frequencies of Bordetella pertussis virulence-associated genes identified from pediatric patients with severe respiratory infections. 61
32334951 2020
11
Protective effects of pharmacological therapies in animal models of multiple sclerosis: a review of studies 2014-2019. 61
31960801 2020
12
A numerical efficient splitting method for the solution of two dimensional susceptible infected recovered epidemic model of whooping cough dynamics: Applications in bio-medical engineering. 61
32078958 2020
13
Modeling the waning and boosting of immunity from infection or vaccination. 61
32272134 2020
14
Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine. 61
32573398 2020
15
Involvement of Gi protein-dependent BKCa channel activation in β2-adrenoceptor-mediated dilation of retinal arterioles in rats. 61
32500188 2020
16
Association of weather variability with resurging pertussis infections among different age groups: A non-linear approach. 61
32135321 2020
17
Emergence of pertactin-deficient pertussis strains in Australia can be explained by models of vaccine escape. 61
32387895 2020
18
Rapid Diagnosis of a Family Cluster of Pertussis Starting from a Child: a Case Report. 61
32538045 2020
19
Efficiency of placental transfer of vaccine-elicited antibodies relative to prenatal Tdap vaccination status. 61
32482459 2020
20
Infant antibody levels following 10-valent pneumococcal-protein D conjugate and DTaP-Hib vaccinations in the first year of life after maternal Tdap vaccination: An open-label, parallel, randomised controlled trial. 61
32448624 2020
21
Extending Timing of Immunization Against Pertussis During Pregnancy and Protection of Premature Infants from Whooping Cough Disease. 61
32569371 2020
22
Whole-Cell Pertussis Vaccination and Decreased Risk of IgE-Mediated Food Allergy: A Nested Case-Control Study. 61
31891824 2020
23
The Law of Unintended Consequences in Pertussis Vaccination: An Ounce of Prevention, a Pound of Cure, and … Food Allergy? 61
32499040 2020
24
Quantity and Quality of Antibodies After Acellular Versus Whole-cell Pertussis Vaccines in Infants Born to Mothers Who Received Tetanus, Diphtheria, and Acellular Pertussis Vaccine During Pregnancy: A Randomized Trial. 61
31418814 2020
25
Paediatric Active Enhanced Disease Surveillance (PAEDS) 2017 and 2018: Prospective hospital-based surveillance for serious paediatric conditions. 61
32536339 2020
26
Delivering prenatal pertussis vaccine through maternity services in England: What is the impact on vaccine coverage? 61
32563605 2020
27
Review of pediatric encephalitis and encephalopathy cases following immunization reported to the Canadian Immunization Monitoring Program Active (IMPACT) from 1992 to 2012. 61
32414652 2020
28
Penta is associated with an increased female-male mortality ratio: cohort study from Bangladesh. 61
32573310 2020
29
Impact of state weights on national vaccination coverage estimates from household surveys in Nigeria. 61
32532542 2020
30
Can economic indicators predict infectious disease spread? A cross-country panel analysis of 13 European countries. 61
31291826 2020
31
Impact of extending the timing of maternal pertussis vaccination on hospitalized infant pertussis in England, 2014 - 2018. 61
32569365 2020
32
Per- and Polyfluoroalkyl Substances Differentially Inhibit Placental Trophoblast Migration and Invasion In Vitro. 61
32219433 2020
33
Influence of SOS-inducing agents on the expression of ArtAB toxin gene in Salmonella enterica and Salmonella bongori. 61
32579098 2020
34
Keep calm and carry on vaccinating: Is anti-vaccination sentiment contributing to declining vaccine coverage in England? 61
32561120 2020
35
Design of γ-AlOOH, γ-MnOOH, and α-Mn2O3 nanorods as advanced antibacterial active agents. 61
32543624 2020
36
Ensilicated tetanus antigen retains immunogenicity: in vivo study and time-resolved SAXS characterization. 61
32513957 2020
37
Barriers and drivers to adult vaccination among family physicians - Insights for tailoring the immunization program in Germany. 61
32409138 2020
38
Prevalence and predictors of taking tetanus toxoid vaccine in pregnancy: a cross-sectional study of 8,722 women in Sierra Leone. 61
32503478 2020
39
The short-chain free fatty acid receptor FFAR3 is expressed and potentiates contraction in human airway smooth muscle. 61
32209026 2020
40
Access, demand, and utilization of childhood immunization services: A cross-sectional household survey in Western Area Urban district, Sierra Leone, 2019. 61
32509292 2020
41
Timeliness of childhood vaccinations in Armenia, 2015-2016. 61
32448619 2020
42
Measuring the cellular memory B cell response after vaccination in patients after allogeneic stem cell transplantation. 61
32519092 2020
43
Oral cavity lesions as a manifestation of the novel virus (COVID-19): a letter-to-editor. 61
32510821 2020
44
Lysophosphatidic acid receptor-2 (LPA2)-mediated signaling enhances chemoresistance in melanoma cells treated with anticancer drugs. 61
32301060 2020
45
Pertussis in Lao PDR: Seroprevalence and disease. 61
32278108 2020
46
Analysis of Multiple Factors Involved in Pertussis-Like Coughing. 61
32075427 2020
47
Expression of small RNAs of Bordetella pertussis colonizing murine tracheas. 61
32227523 2020
48
Diphtheria, tetanus and pertussis: unequal vaccine siblings with distinct characteristics. 61
32516807 2020
49
Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety. 61
32499067 2020
50
Maternity staff immunization coverage against pertussis and maternal vaccination practices: Results of a 2017 cross-sectional survey in five public maternity hospitals. 61
31375373 2020

Variations for Pertussis

Expression for Pertussis

Search GEO for disease gene expression data for Pertussis.

Pathways for Pertussis

Pathways related to Pertussis according to KEGG:

36
# Name Kegg Source Accession
1 Pertussis hsa05133

Pathways related to Pertussis according to GeneCards Suite gene sharing:

(show top 50) (show all 194)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.21 TNF TLR4 OPRM1 MYD88 MAPK10 MAPK1
2
Show member pathways
14.03 TNF MAPK10 MAPK1 JUN ITGB2 ITGAM
3
Show member pathways
14 TNF MAPK10 MAPK1 JUN ITGB2 ITGAM
4
Show member pathways
13.88 MAPK10 MAPK1 JUN ITGB2 ITGAM IL6
5
Show member pathways
13.86 TNF TLR4 MAPK10 MAPK1 JUN IL6
6
Show member pathways
13.75 TNF MAPK10 MAPK1 JUN ITGB2 ITGAM
7
Show member pathways
13.62 MAPK10 MAPK1 JUN ITGB2 ITGAM GNAZ
8
Show member pathways
13.58 TNF OPRM1 MYD88 MAPK1 ITGB2 ITGAM
9
Show member pathways
13.51 TNF MAPK10 MAPK1 JUN IL6 IL1B
10
Show member pathways
13.47 TNF MAPK10 JUN IL6 IL1B IL1A
11
Show member pathways
13.44 TNF TLR4 MYD88 MAPK10 MAPK1 JUN
12
Show member pathways
13.42 TNF MAPK10 MAPK1 JUN IL6 GNAI1
13
Show member pathways
13.33 TNF MAPK10 MAPK1 IL6 IL1B IL1A
14
Show member pathways
13.31 MAPK10 MAPK1 JUN IL6 IL1A FOS
15
Show member pathways
13.28 MAPK10 MAPK1 JUN GNAZ GNAI1 GNA15
16
Show member pathways
13.27 TNF MAPK10 MAPK1 JUN IL6 GNAZ
17
Show member pathways
13.27 MAPK1 ITGB2 ITGAM IL6 GNAZ GNAI1
18
Show member pathways
13.25 MAPK10 MAPK1 JUN IL6 GNAI1 GNA15
19
Show member pathways
13.22 OPRM1 MAPK1 GNAZ GNAI1 GNA15 GNA14
20
Show member pathways
13.22 MAPK1 JUN GNAZ GNAI1 GNA15 GNA14
21
Show member pathways
13.2 MAPK10 MAPK1 JUN GNAZ GNAI1 GNA15
22
Show member pathways
13.19 MAPK10 JUN ITGB2 ITGAM GNAZ GNAI1
23
Show member pathways
13.17 TNF TLR4 MYD88 MAPK10 MAPK1 JUN
24
Show member pathways
13.14 TNF MAPK10 MAPK1 JUN ITGB2 ITGAM
25
Show member pathways
13.11 MAPK10 MAPK1 JUN ITGB2 ITGAM IL6
26
Show member pathways
13.1 MAPK10 MAPK1 JUN GNAI1 GNA15 GNA14
27
Show member pathways
13.08 MAPK1 ITGB2 ITGAM GNAI1 GNA15 GNA14
28
Show member pathways
13.06 MAPK10 MAPK1 JUN ITGB2 ITGAM FOS
29
Show member pathways
13.06 TNF ITGB2 IL6 IL1B IL1A IL10
30
Show member pathways
13.06 TNF TLR4 MYD88 MAPK10 MAPK1 JUN
31
Show member pathways
13.05 MAPK10 MAPK1 JUN ITGB2 GNAZ GNAI1
32
Show member pathways
13.05 MAPK10 MAPK1 JUN ITGB2 ITGAM GNAZ
33 13.04 MAPK10 MAPK1 JUN IL6 GNAI1 FOS
34 13 TNF MYD88 MAPK10 MAPK1 JUN IL1B
35
Show member pathways
12.99 TNF TLR4 MYD88 MAPK10 MAPK1 JUN
36
Show member pathways
12.96 TNF TLR4 MYD88 MAPK10 MAPK1 JUN
37
Show member pathways
12.92 OPRM1 MAPK10 MAPK1 JUN GNAI1 GNA15
38
Show member pathways
12.91 TNF MAPK1 JUN IL6 FOS
39
Show member pathways
12.9 MAPK10 MAPK1 GNAI1 FOS ADCY10
40
Show member pathways
12.89 TNF MYD88 MAPK10 MAPK1 JUN FOS
41
Show member pathways
12.89 TNF TLR4 MYD88 IL6 IL1B IL1A
42
Show member pathways
12.89 TNF MAPK10 MAPK1 JUN ITGB2 ITGAM
43
Show member pathways
12.89 TNF MAPK10 MAPK1 JUN IL1B IL1A
44
Show member pathways
12.88 MAPK10 MAPK1 ITGB2 ITGAM GNAI1
45
Show member pathways
12.87 MAPK10 MAPK1 JUN IL1B GNAZ GNAI1
46
Show member pathways
12.86 TNF MAPK10 MAPK1 JUN IL10 GNA15
47
Show member pathways
12.86 TNF TLR4 MAPK10 MAPK1 JUN IL6
48
Show member pathways
12.85 TNF TLR4 MYD88 MAPK10 MAPK1 JUN
49
Show member pathways
12.82 MAPK1 GNAZ GNAI1 GNA15 GNA14
50
Show member pathways
12.8 TNF MAPK1 IL6 IL1B IL10 FOS

GO Terms for Pertussis

Cellular components related to Pertussis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.13 TNF TLR4 OPRM1 MYD88 MAPK10 MAPK1
2 membrane raft GO:0045121 9.35 TNF OPRM1 ITGB2 ITGAM GNAI1
3 transcription factor AP-1 complex GO:0035976 9.26 JUN FOS
4 integrin alphaM-beta2 complex GO:0034688 9.16 ITGB2 ITGAM
5 heterotrimeric G-protein complex GO:0005834 8.92 GNAZ GNAI1 GNA15 GNA14

Biological processes related to Pertussis according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.27 TNF TLR4 JUN IL6 IL1B IL1A
2 positive regulation of transcription, DNA-templated GO:0045893 10.18 TNF MAPK1 JUN IL6 IL1B IL10
3 signal transduction GO:0007165 10.18 TLR4 OPRM1 MYD88 MAPK10 MAPK1 IL6
4 immune response GO:0006955 10.13 TNF TLR4 IL6 IL1B IL1A IL10
5 positive regulation of gene expression GO:0010628 10.12 TNF TLR4 MYD88 MAPK1 IL6 IL1B
6 regulation of gene expression GO:0010468 10.11 MYD88 MAPK10 MAPK1 IL10 FOS
7 negative regulation of cell proliferation GO:0008285 10.09 OPRM1 JUN IL6 IL1B IL1A IL10
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.05 TNF TLR4 OPRM1 JUN
9 leukocyte migration GO:0050900 10.04 TNF ITGB2 ITGAM IL1B
10 Fc-epsilon receptor signaling pathway GO:0038095 10.03 MAPK10 MAPK1 JUN FOS
11 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.03 TNF TLR4 MYD88 IL1B IL1A
12 aging GO:0007568 10.02 MAPK1 JUN ITGB2 IL10 FOS
13 positive regulation of angiogenesis GO:0045766 10.01 ITGB2 IL1B IL1A CXCL8
14 positive regulation of DNA-binding transcription factor activity GO:0051091 9.97 TNF IL6 IL1B IL10
15 platelet activation GO:0030168 9.96 MAPK1 IL6 GNA15 GNA14
16 positive regulation of JNK cascade GO:0046330 9.96 TNF TLR4 MYD88 IL1B
17 activation of MAPK activity GO:0000187 9.96 TNF TLR4 MAPK10 MAPK1 IL1B
18 neutrophil chemotaxis GO:0030593 9.93 ITGB2 IL1B CXCL8
19 phagocytosis GO:0006909 9.93 TLR4 MYD88 ITGB2
20 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.93 GNAZ GNAI1 GNA15 GNA14
21 apoptotic signaling pathway GO:0097190 9.92 TNF TLR4 ITGAM
22 response to glucocorticoid GO:0051384 9.92 TNF IL6 IL10
23 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.91 TNF TLR4 IL1B
24 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.91 OPRM1 GNAZ GNAI1
25 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.91 TNF TLR4 MYD88 ITGB2 IL6 IL1B
26 inflammatory response GO:0006954 9.91 TNF TLR4 MYD88 ITGB2 IL6 IL1B
27 JNK cascade GO:0007254 9.9 TNF MYD88 MAPK10
28 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.9 TNF JUN IL10
29 positive regulation of smooth muscle cell proliferation GO:0048661 9.9 TNF MYD88 JUN IL6
30 positive regulation of interferon-gamma production GO:0032729 9.89 TNF TLR4 IL1B
31 positive regulation of neuron death GO:1901216 9.89 ITGB2 ITGAM FOS
32 cellular response to reactive oxygen species GO:0034614 9.88 MAPK1 JUN FOS
33 cellular response to cadmium ion GO:0071276 9.87 MAPK1 JUN FOS
34 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.87 TNF IL1B IL1A
35 negative regulation of interleukin-6 production GO:0032715 9.87 TNF TLR4 IL10
36 positive regulation of nitric oxide biosynthetic process GO:0045429 9.87 TNF TLR4 ITGB2 IL1B
37 positive regulation of cytokine secretion GO:0050715 9.85 TNF IL1A IL10
38 positive regulation of JAK-STAT cascade GO:0046427 9.85 TNF IL6 IL10
39 positive regulation of vascular endothelial growth factor production GO:0010575 9.85 IL6 IL1B IL1A
40 negative regulation of neurogenesis GO:0050768 9.84 TNF IL6 IL1B
41 positive regulation of interleukin-6 secretion GO:2000778 9.84 TNF TLR4 IL1B IL1A
42 positive regulation of chemokine production GO:0032722 9.83 TNF TLR4 IL6
43 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.83 TNF JUN IL10 FOS
44 positive regulation of glial cell proliferation GO:0060252 9.82 TNF IL6 IL1B
45 toll-like receptor 4 signaling pathway GO:0034142 9.82 TLR4 ITGB2 ITGAM
46 microglial cell activation GO:0001774 9.81 TNF JUN ITGB2 ITGAM
47 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.8 TNF IL1B IL10
48 positive regulation of interleukin-8 production GO:0032757 9.8 TNF TLR4 MYD88 IL1B
49 positive regulation of interleukin-6 production GO:0032755 9.8 TNF TLR4 MYD88 IL6 IL1B
50 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.79 TNF ITGB2 IL6

Molecular functions related to Pertussis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.41 TNF TLR4 OPRM1 MYD88 MAPK10 MAPK1
2 cytokine activity GO:0005125 9.63 TNF IL6 IL1B IL1A IL10 CXCL8
3 G protein-coupled receptor binding GO:0001664 9.62 GNAZ GNAI1 GNA15 GNA14
4 type 2A serotonin receptor binding GO:0031826 9.43 GNA15 GNA14
5 interleukin-1 receptor binding GO:0005149 9.43 MYD88 IL1B IL1A
6 complement component C3b binding GO:0001851 9.4 ITGB2 ITGAM
7 G protein-coupled serotonin receptor binding GO:0031821 9.37 GNAZ GNAI1
8 G-protein beta/gamma-subunit complex binding GO:0031683 9.26 GNAZ GNAI1 GNA15 GNA14
9 guanyl nucleotide binding GO:0019001 8.92 GNAZ GNAI1 GNA15 GNA14

Sources for Pertussis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....